Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesRelationships between FSH, inhibin B, anti-Mullerian hormone and testosterone during long-term treatment with the GnRH-agonist Histrelin in patients with prostate cancer
European Journal of Endocrinology, 10/30/09
Eldar–Geva T et al. – The secondary increase in FSH following initial suppression with the implant is probably related to impaired inhibin B secretion. The lack of inhibin B response to the secondary increase in FSH suggests that long–term exposure of Sertoli–cells to GnRH–agonist impairs their function. This effect appears to be selective since unlike inhibin B, AMH increased. In the absence of testosterone, FSH has a role in AMH regulation.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven
The Oncologist, 10/28/09
Sponsor
Article Search
Sponsor